BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

Exclusion Criteria

• •History of or positive test result at screening for human immunodeficiency virus, or for hepatitis C virus antibody, or current Hepatitis B infection.
• •Clinically significant diseases or conditions as determined by the investigator.
• •Major surgery within 30 days prior to the Screening Visit or that is scheduled to occur during the study.
• •Previous participation in a study with neurotrophic factors (e.g., nerve growth factor).
• •Participation in a study with another investigational drug or approved therapy for investigational use within 3 months prior to Day 1.
• •Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec Inc. (Biogen Idec), make the subject unsuitable for enrollment